学术报告

您所在的位置:首页 >> 学术科研 >> 学术报告 >> 正文

药学前沿大讲堂第356讲

点击数:115 作者:药学院 编辑:药学院 来源:药学院 提醒时间:2018-04-10

   :Structure-Based Discovery of Potent RORγt Modulators- From Drug Concept to Clinic Candidate

报告人: 李翔 博士,VP, Head of Integrated BiologyBioDuro, LLC. ( 润诺生物科技(上海)有限公司,保诺科技(北京)有限公司)

主持人徐峻 教授,中山大学药学院

   : 2018年410日(周二)09:30-10:30

    : 中山大学东校园药学院112会议室

报告人简介:

    Dr. Xiang Li is currently VP, Head of Integrated Biology, in charge of all the in-vitro and in-vivo biology departments, including Discovery Biology, Pharmacology and Oncology at BioDuro LLC. A seasoned scientific leader in innovative drug discovery R&D, Dr. Xiang Li has extensive experience in the entire early drug discovery process, including new target proposal and selection, hit-finding strategy, lead identification (LI), lead optimization (LO) and in-depth evaluation of clinical candidates. Prior to joining BioDuro, Dr. Li had worded at Boehringer Ingelheim (BI) for 21 years in autoimmune, cardiovascular and metabolic disease areas, and scientifically contributed to advancing multiple compounds into clinical trials. Dr. Li is a recognized expert in Structure-Based Drug Discovery (SBDD) and Fragment-Based Lead Discovery (FBLD). He is the recipient of a President’s Award of “Fragment-Based Alternate Lead Discovery” at BI.

    Dr. Li graduated from the University of Science and Technology of China with a B. Sc. Degree in Molecular Biophysics (1986). Dr. Li earned his D. phil. degree(1992) at the University of Oxford with Professor C.M. Dobson, FRS under a Sino-British Friendship Scholarship, and completed a CRI Postdoctoral Fellowship in General of Cancer Immunology with Professor P.E. Wright(NAS member) at The Scripps Research Institute.

 

欢迎广大师生踊跃参与!


分享本文: